BOTHELL, WA and VANCOUVER, May 2 /CNW/ - OncoGenex Pharmaceuticals, Inc.
(NASDAQ: OGXI) announced that the Company's first quarter 2011
financial results will be released on Monday, May 9, 2011 after the
NASDAQ Global Market closes at 4:00 p.m. ET, and that the Company will
host a conference call and live webcast at 4:30 p.m. ET that afternoon.
Management will discuss the company's financial results and provide an
update on the business.
To access the webcast, log on to the Investor Relations page of the
OncoGenex website at www.oncogenex.com. Alternatively, you may access
the live conference call by dialing (877) 606-1416 (U.S. & Canada) or
(707) 287-9313 (International). A webcast replay will be available
approximately two hours after the call and will be archived on
www.oncogenex.com for 90 days.
About OncoGenex Pharmaceuticals
OncoGenex is a biopharmaceutical company committed to the development
and commercialization of new cancer therapies that address treatment
resistance in cancer patients. OncoGenex has a diverse oncology
pipeline, with each product candidate having a distinct mechanism of
action and representing a unique opportunity for cancer drug
development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NASDAQ:
TEVA) have entered a global collaboration and license agreement to
develop and commercialize OncoGenex' lead drug candidate, custirsen.
Custirsen is currently in Phase 3 clinical development as a treatment
in men with metastatic castrate-resistant prostate cancer. The
companies plan to begin Phase 3 development of custirsen in first-line
treatment of advanced, unresectable non-small cell lung cancer in 2011.
OGX-427 is in Phase 2 clinical development; CSP-9222 and OGX-225 are
currently in pre-clinical development.
SOURCE OncoGenex Pharmaceuticals, Inc.
For further information: